Fintel reports that on January 8, 2025, JMP Securities initiated coverage of Context Therapeutics (NasdaqCM:CNTX) with a ...

Context Therapeutics (NASDAQ:CNTX – Get Free Report) was upgraded by Citizens Jmp to a “strong-buy” rating in a note issued ...

Context Therapeutics (CNTX) has received a new Buy rating, initiated by JMP Securities analyst, Silvan Tuerkcan.Stay Ahead of the ...

Shares of Context Therapeutics Inc. rose over 7% in Wednesday's pre-market trading after JMP Securities initiated coverage ...

Light Horse Therapeutics Inc., a developer of first-in-class small molecule therapeutics, announced a multi-target collaboration with Novartis to identify and develop potentially first-in-class ...

Piper Sandler has reaffirmed its Overweight rating on shares of Context Therapeutics (NASDAQ: CNTX) with a consistent price target of $4.50. The firm's confidence is bolstered by... Piper Sandler ...

Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule ...

Scientists have developed inhalable lung cancer therapeutics utilizing mucoadhesive proteinic nanoparticles.

January 3, 2025) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Applied Therapeutics, Inc. (NASDAQ: APLT) securities between January 3, 2024 and December ...

Lung cancer remains one of the deadliest cancers globally. Non-small cell lung cancer (NSCLC), which accounts for 85% of all lung cancer cases, is particularly challenging to treat due to difficulties ...

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.